Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

计划入组 410 人 · 首次发布于 2007 年 9 月 11 日

Capital Mãe

计划入组 446 人

CAPITAL OFFLOAD-SHOCK

计划入组 456 人 · 首次发布于 2026 年 8 月 11 日

trimethylangelicin (Rare Partners)

DLL3(Molecular Partners)

177Lu/225Ac labeled alphavbeta3-integrin targeting peptidomimetics (Advanced Innovative Partners)

Proximity Capital Partners, LLC

United States

HAMILTON CAPITAL PARTNERS INC CANADIAN EQTY YIELD MAXIMIZE CLASS E ETF

United States

Hercules Capital

United States

Gifthealth Acquires Occam Health Services to Create Digital Pharmacy Platform for Enhanced Patient Access

Bluebird Bio Goes Private in $29M Deal with Carlyle and SK Capital Partners

Moleculent Secures $20 Million to Advance Cell Communication Mapping Technology